cyrilzakka/clinical-trials huggingface dataset:
Comparison of Breathing Events Detected by the SleepStyle 200 Auto Continuous Positive Airway Pressure (CPAP) Device to Attended Polysomnography

Obstructive Sleep Apnoea (OSA) is a common sleep-breathing disorder affecting around 2-4% of the population and is characterised by loud snoring, periodic collapse of the upper airway particular to sleep, sleep fragmentation, and sometimes daytime sleepiness. Health consequences include impaired cognitive functioning, quality of life, mood, and increased cardiovascular disease risk. Epidemiological studies have demonstrated that increased morbidity and mortality in a dose response manner with increasing severity of sleep disordered breathing.

The standard treatment for OSA is nasal Continuous Positive Airway Pressure (CPAP), which consists of pressurized air applied to the nose via a mask. Generally a single, optimal pressure is prescribed for a patient based on a full night or partial night study during which the pressure is adjusted by a technician until all sleep disordered breathing (SDB) events are abolished. Despite therapy efficacy, compliance to CPAP therapy is sub-optimal.

Due to low compliance it has become common for healthcare providers to follow up subject therapy efficacy through reporting software inherent in many current CPAP devices. Healthcare providers can use this reported data to make appropriate treatment decisions. For this reason the data needs to be accurate. The SleepStyle™ 200 Auto Series CPAP humidifier is an auto adjusting CPAP which stores comprehensive compliance data. The aim of this study is to compare the reliability of the SleepStyle™ 200 Auto Series CPAP data to laboratory-based PSG in detecting sleep disordered breathing.

Hypothesis: The SleepStyle™ 200 Auto Series reporting features accurately detects indices of sleep disordered breathing.


Eligibility Criteria:
Inclusion Criteria:

* Apnea Hypopnea Index (AHI) \>15 from diagnostic night
* ≥18 years of age

Exclusion Criteria:

* Contraindicated for CPAP use
Active and Healthy Kids in Telemark - a School Based Health Promoting Intervention

The study examine possible changes in physical activity, nutrition, and psychosocial health following the intervention "Active and Healthy Kids in Telemark". The intervention schools will received the intervention, whereas the control schools will continue as usual.

School based, health promoting interventions with focus on increase physical activity and improved nutrition seems to be a good solution to the challenges with low physical activity level, poor physical fitness, poor nutrition and psychosocial health challenges among children and adolescents. Low physical activity levels and physical fitness is recognized as one of the major public health challenges in the 21st century, and it negatively affects cognitive skills and academic performances. Providing school based health promoting interventions makes it easier to reach all children and adolescents regardless of social and cultural background, and hence reduce social inequalities in health.

Eligibility Criteria:
Inclusion Criteria:

* Pupil 8th grade

Exclusion Criteria:

* Inadequate language skills to complete questionnaire
Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Switching Antiplatelet

This study aims to describe antiplatelet therapy in ACS in Andalusia and make an assessment of efficacy and safety of hospital use Prasugrel / ticagrelor vs. Clopidogrel and Prasugrel switching to / ticagrelor patients pretreated with clopidogrel.

The management of acute coronary syndrome has changed in recent years as reflected in the new Clinical Practice Guidelines of the European Society of Cardiology for the management of ACS with or without ST segment elevation, with the development and increased accessibility of the angiography and percutaneous coronary intervention and the arrival of the new antiplatelet (Prasugrel and Ticagrelor).

The ACS encompasses several clinical entities where dual antiplatelet therapy remains the basis of antiplatelet therapy and one of the mainstays of treatment. But the emergence of Prasugrel and Ticagrelor have changed the classical management with aspirin plus clopidogre

Eligibility Criteria:
Inclusion Criteria:

* Patients admitted to the Coronary Care Unit at the time defined with an initial diagnosis of ACS.

Exclusion Criteria:

* Myocarditis, Takotsubo syndrome, pulmonary thromboembolism.
* Secondary MI or type 2, caused by an increase in demand or decrease oxygen (anemia, tachycardia, hypotension, heart failure, etc.). 11
* Patients under 18 years.
A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

PF-03893787, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.


Eligibility Criteria:
Inclusion Criteria:

* Males and females 18-60 years.
* Mild asthma
* Atopic to allergens

Exclusion Criteria:

* Unstable asthma.
* Smokers or recent ex-smokers
* Recent allergen challenge
Short-Term Effects of Whole-Body Vibration on Upper Extremity Function in Subjects With Poststroke Hemiplegia

To investigate the effect of whole body vibration on upper limb motor function in hemiplegic patients with subacute stroke


Eligibility Criteria:
Inclusion Criteria:

* After unilateral stroke 1 to 6 months
* An ischemic or hemorrhagic poststroke hemiplegia
* No cognitive impairment
* Able to reach Brunnstrom stage II or above in the proximal and distal parts of the arms
* No excessive pain in the more affected upper extremity
* All subjects agreed to participate in the study after receiving explanations regarding the purpose and procedures of the experiment, and they signed an informed consent statement before participation

Exclusion Criteria:

* Unsteadiness
* Accompanied by important organs (such as heart, liver, lung, kidney) dysfunction or malignant tumors
* Contraindications to general vibration training exist
* Combined with other diseases causing upper limb dysfunction
The Facing Pain Study

This randomized trial will create and compare two private Facebook conditions for patients with chronic pain. The control condition will be comprised of groups of patients who communicate without much clinician / moderator input, and the experimental condition will have a clinician moderating and teaching patients several techniques designed to facilitate social disclosure, validation, and emotional engagement with avoided activities.

This study will investigate the effectiveness of a private Facebook group for individuals in chronic pain. Currently, more than 100,000 individuals with chronic pain (ICPs) participate in Facebook groups, seeking support from others in similar situations. There are currently some online self-management programs for ICPs; however, most lack a peer support aspect, as they are individualized, self-directed, and focus on instructing patients in how to manage their pain. The goals of the proposed online pain support group are: 1) to provide peer-to-peer social support for individuals with chronic pain; and 2) to disseminate psychosocial pain management techniques using a social media platform. Screened participants will be assigned to one of two conditions: a Facebook group similar to the groups that are occurring naturally (control condition) or an enhanced Facebook group that is moderated by clinicians and offers psychosocial pain management techniques (experimental condition). Both conditions involve peer-to-peer healthcare and support, but the experimental group additionally includes components such as psychoeducation about pain neuroscience, emotional validation training, guided emotional disclosure, and activities to overcome emotional and behavioral avoidance. Findings from this study will offer important information about the impact of Facebook support groups on pain outcomes, and test whether psychosocial pain interventions can be disseminated using a social media platform.

Eligibility Criteria:
Inclusion Criteria:

* Must have chronic pain (i.e., pain that persists for greater than 3 months)
* Must be fluent at reading and writing in English
* Must have an active Facebook account and check Facebook at least 3 times a week

Exclusion Criteria:

* Terminal illness such as cancer
* Active psychosis (e.g., hallucinations, delusions)
Study on Human Glenoid Cavity and Acetabulum

1 - study morphological and morphometric features of the glenoid cavity in human scapulae bone and its function.

2- study morphological and morphometric features of the acetabulum in human hip bone and its function.

study morphological features of the glenoid cavity and to measure various dimensions of the glenoid in dry human scapulae bone and correlation to its function.

The knowledge of normal anatomical features and variations of the shape and size of glenoid cavity are prerequisites for complete understanding of the mechanics of shoulder joint, this information has clinical application in shoulder arthroplasty, gleno-humeral instability and rotator cuff tear management.

study morphological features of the acetabulum and to measure various dimensions of the acetabulum in dry human hip bone and correlation to its function.

Knowledge of the dimensions of acetabulum are vital to understand the mechanics of hip joint, and will assist the prosthetists to construct the suitable prostheses

Eligibility Criteria:
Inclusion Criteria:

* The scapulae with clear and intact glenoid cavity will be used for the study. The hip bones with clear and intact acetabulum will be used for the study

Exclusion Criteria:

* Bones with gross damage or anomalies will be excluded from the study.
Evaluation of Three Irrigants, Sodium Hypochlorite, Chlorhexidine and Combination of CHX+H2O2 in Endodontic Treatment.

This study will evaluate the synergistic effect of CHX + H2O2 when used as an irrigant during biomechanical preparation.in root canal treatment on periapical healing and compared with Chlorhexidine( CHX) and Sodium Hypochlorite (NaOCl).

After a thorough history, clinical and radiographic examination with all eligibility confirmation, written informed consent will be taken from the patient after explaining the procedure and its associated risks and benefits. Patients randomly allocated to one of the three study groups Sodium hypochlorite (NaOCl), Chlorhexidine (CHX) and combination of (CHX+H2O2). All three irrigants will be used according to standard protocol during biomechanical preparation. Pain analysis will be carried out preoperatively and postoperatively at every 6 hours for 1 day and then every 24 hours till 7 days after the intervention. All the subjects will be followed up for evaluation of clinical and radiographic success at 3, 6 months and 1year.

Eligibility Criteria:
Inclusion Criteria:

* All patients over 18 years of age.
* Mature permanent mandibular molars.
* A radiographic evidence of periapical radiolucency (minimum size \> 2mm×2mm) and a diagnosis of pulpal necrosis, as confirmed by the negative response to cold and electrical tests; and absence of bleeding on entering the pulp chamber.

Exclusion Criteria

* Diabetics, immunocompromised patients, pregnant females, any systemic disease.
* Patients with a history of analgesic intake within the past 3 days and antibiotics in the last month.
* Patients with pockets ≥ 4mm or having marginal or furcal bone loss due to periodontitis.
* Non-restorable tooth, fractured, perforated roots and inflammatory root resorption.
* Teeth those are not suitable for rubber dam isolation.
* Primary teeth.
ENdothelial Healing Assessment With Novel Coronary tEchnology

This is a prospective, non-randomized, single center clinical trial to assess neointimal coverage on the stent or scaffold strut and apposition of SYNERGY™ and ABSORB in minimum of 12 eligible human subject at 4 month and 12 month after stent or scaffold implantation using OCT and CAS

All of the subject will received SYNERGY™ stent in one of the blocked coronary artery and ABSORB scaffold strut in the other artery. All subjects must have 2 coronary arteries stenosis of more than 70%.

Eligibility Criteria:
Inclusion Criteria:

1. Subject is 20 years old or older
2. Subject or legally authorized representative must provide written informed consent prior to any study related procedure, per site requirements.
3. Subject must have evidence of myocardial ischemia (eg stable or unstable angina, silent ischemia) suitable for elective PCI
4. Significant narrowing of at least 70% stenosis of de novo lesion (QCA or visual estimation) in 2 different native coronary arteries.
5. Subject is eligible for to undergo OCT and CAS examination at 4 months and 12 months after stent or scaffold implantation.
6. Subject is able to take dual anti-platelet therapy up to one year following the index procedure and anticoagulants prior/during the index procedure

Exclusion Criteria:

1. Subject had an acute myocardial infarction (STEMI or NSTEMI) within 24 hours of the index procedure
2. Subject has known left ventricular ejection fraction (LVEF) \< 30%
3. Subject is receiving hemodialysis
4. Target vessel were treated by PCI within 12 months
5. Target lesion is located within a saphenous vein graft or an arterial graft
6. Target lesion is located in ostium
7. Target lesion is located highly tortuous equal to or greater than 60 degrees
8. Target lesion with TIMI flow 0 (total occlusion)
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.

This study will use a multicenter, randomized, open-label, active-controlled, dose-titration, parallel group design, in approximately pediatric patients with detrusor overactivity associated with a neurological condition.

Eligibility Criteria:
Inclusion Criteria:

* Pediatric patient with a diagnosis of detrusor overactivity associated with a neurological condition;
* Use clean intermittent catheterization
* On stable dose of oral oxybutynin before participation

Exclusion Criteria:

* Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency
* Have any medical condition that precludes their participation in the study or may confound the outcome of the study
Is a Collective Person-centered Dialogue Intervention for Hospitalised COPD Patients Feasible?

The aim of this mixed methods trial is to investigate the feasibility of a collective person-centred dialogue (COPE-D) intervention delivered by an interdisciplinary team for a population of patients hospitalised and diagnosed with COPD and their relatives.

The main questions it aims to answer are:

* The clinical uncertainties: What components of the COPE-D intervention are delivered to the included patients? (The data will be collected from the patient's journal record)
* The clinical uncertainties: How acceptable is the COPE-D intervention for the patients, relatives, and the interdisciplinary team? (Answered by patient and relative interviews with a structured interview guide before discharge and 14 days after hospitalisation, and by the interdisciplinary team using focus-group interviews after the intervention enrolment).
* The procedural uncertainties: Are the patients willing to engage in the trial? (Estimated by the inclusion rate).

The interdisciplinary team will be instructed to deliver and document the COPE-D intervention. The primary focus of COPE-D intervention is to prepare and enhance the patient's and relative's ability to regain their everyday life after discharge. The COPE-D intervention includes a dialogue tool based on a needs assessment, an action plan template, and a patient guide that prepares for discharge.

The interdisciplinary team will collaborate with COPD patients and their relatives to:

1. Assess the patient's need for nutrition and physical activity support, both during and after hospitalisation using the dialogue tool.
2. Develop an action plan for nutrition and physical activity support using the action plan template.
3. The interdisciplinary team will provide, adjust, and document the nutritional and physical activity support provided by the action plan.
4. Prior to discharge, patients and their relatives are given a discharge guide with pre-defined questions to ask healthcare professionals, a contact telephone number to the outpatient clinic for follow-up if needed, and information about prescriptions for oral nutritional supplementation.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with COPD
* Speak and understand Danish.

Exclusion Criteria:

* Patients in the end-of-life phase.
* Patients living in nursing homes.
* Patients with cognitive impairments avoiding participation.
Evaluating the Initial Lens Handling Experience of Neophyte Contact Lens Wearers Fitted With Precision1 and 1-Day Acuvue Moist Contact Lenses

The initial subjecting handling experience of neophyte contact lens wearers with Precision1 will be compared to that with a daily disposable lens which mas been on the market for numerous years (1-Day ACUVUE Moist).


Eligibility Criteria:
Inclusion Criteria:

1. Is between 18 and 40 years of age inclusively and has full legal capacity to volunteer;
2. Has read and signed an information consent letter;
3. Is willing and able to follow instructions and maintain the appointment schedule;
4. Is a neophyte who has no history of any previous contact lens handling experience;
5. Has a refraction cyl ≤1.00DC in either eye (after vertexing to corneal plane);
6. Has visual acuity ≤0.20 logMAR each eye with study lenses;
7. Demonstrates acceptable fit with study lenses;
8. Demonstrates the ability to successfully insert and remove the study lenses 3 times for each eye (contralateral CL handling, so that each lens type inserted and removed 3x on same eye);
9. Is willing to wear study CLs at least 5 days per week and 6 hours per day throughout the study

Exclusion Criteria:

1. Is participating in any concurrent clinical or research study;
2. Has any known active\* ocular disease and/or infection;
3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
4. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
5. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
6. Is pregnant, lactating or planning a pregnancy at the time of enrolment (by self-report);
7. Is aphakic;
8. Has undergone refractive error surgery;
9. Has taken part in another clinical research study within the last 14 days;
10. Any ocular and/or systemic conditions or concomitant medication to contraindicate contact lens wear or be expected to interfere with the primary outcome variables.

    * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
Covid-19 Long Immunité IMagerie (CLIIM)

Covid-long pathology affects a large number of patients, and represents a major medical, economic and societal challenge. To date, we have no objective criterion for a definitive diagnosis, nor any predictive tool for monitoring the evolution of Covid-long. Based on recruitment from the infectious diseases department of Nice University Hospital, the investigator's team wants to conduct an innovative pathophysiological study to better define the disease and identify specific biomarkers that could subsequently be used as a diagnostic tool for Covid-long. 120 participants will be initially included for the model learning phase: 60 controls in the CL- cohort and 60 patients in the CL+ cohort. Then 80 patients (40 CL+ and 40 Cl-) will be enrolled for the model validation phase.


Eligibility Criteria:
FOR CL+ PATIENTS

Inclusion Criteria:

* Case definition in line with WHO Delphi process

Exclusion Criteria:

* History of chronic fatigue syndrome diagnosed before or after Covid.
* History of progressive psychiatric pathology.
* History of acute Covid requiring admission to intensive care and mechanical ventilation.
* No social security affiliation.

FOR CONTROL (CL-)

Inclusion Criteria:

* History of acute COVID-19, mild, moderate or severe (episode at least 3 months at the time of inclusion).
* Absence of persistent symptoms more than 3 months after first Covid symptoms (or mild not affecting daily activities).

Exclusion Criteria:

* History of progressive psychiatric pathology.
* History of acute Covid requiring admission to intensive care and mechanical ventilation.
* No social security affiliation.
* Pregnant or breast-feeding.